Thermal Field Distributions of Ablative Experiments Using Cyst-mimicking Phantoms

Huang, Xiaowen; Nie, Fang; Wa, Zeng-Cheng; Hu, Hang-Tong; Huang, Qing-xiu; Guo, Huanling; Zheng, Qiao; Xie, Xiaoyan; Wang, Wei; Lü, Ming-De

doi:10.1016/j.acra.2017.11.010

Cited by 7 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Temperatures exceeding 60°C can cause cellular membrane lysis, protein denaturation, and enzyme inactivation, which lead to rapid coagulative necrosis ( 15 , 44 ). Second, in the tumor periphery beyond the border of immediate tissue coagulation, TA can cause indirect thermal injuries, including vascular injury, ischemia-reperfusion, release of lysosomal contents ( 16 , 45 , 46 ). Finally, TA may result in the release of abundant immunogenic intracellular substrates, which can initiate and upregulate steps in the cancer immunity cycle required to elicit an anti-cancer immune response ( 47 , 48 ).…”

Section: Discussionmentioning

confidence: 99%

Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis

Yang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThermal ablation (TA) is considered a safe alternative to surgical resection for the treatment of non-small cell lung cancer (NSCLC). While previous studies have shown that TA is beneficial for stage I NSCLC patients, however, few have reported on TA efficacy in patients with stage II-III NSCLC. The current study investigated the impact of TA on the overall survival (OS) and cancer-specific survival (CSS) of patients with stage II-III NSCLC.MethodsData on patients with stage II-III NSCLC who did not undergo surgical resection between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), Kaplan-Meier survival curves, and Cox regression were used for statistical analyses.ResultsA total of 57,959 stage II-III NSCLC patients who did not undergo surgical resection were included in this study, 261 of whom received TA. Overall, TA was associated with a longer OS (p = 0.035) and CSS (p = 0.005) than non-ablation. After 1:3 PSM, 252 patients receiving TA and 732 patients not receiving ablation were enrolled in the matched cohort. The OS (p = 0.047) and CSS (p = 0.029) remained higher in the TA group than in the non-ablation group after PSM. Cox regression analysis showed that age, sex, primary tumor site, pathological type, tumor size, radiotherapy, chemotherapy, and thermal ablation were independently associated with OS and CSS (p <0.05). Subgroup analysis found that the advantages of TA were more pronounced among individuals ≥70 years of age, with tumor size ≤3.0 cm, or who did not receive radiotherapy.ConclusionTA could be an effective alternative treatment for stage II-III NSCLC patients unsuitable for surgical resection, particularly those ≥70 years of age, with tumor size ≤3.0 cm, or who have not received radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis

Yang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Several published studies have compared the outcomes following RFA and MWA. Bench tests [2][3][4][5], pre-clinical [6,7] and clinical studies [6] have compared coagulation zone size and treatment outcomes after both energy modalities. While some recent pre-clinical and clinical studies have compared the pro-tumorigenic effects of RFA and MWA [8][9][10], only one recent ex vivo study indirectly compared the volume of the RFA/MWA transition zone, its relationship with residual thermal energy after ablation, and the effect of subsequent cooling on reducing the transition zone [11].…”

Section: Introductionmentioning

confidence: 99%

How large is the periablational zone after radiofrequency and microwave ablation? Computer-based comparative study of two currently used clinical devices

Trujillo

Prakash

Faridi

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: To compare the size of the coagulation (CZ) and periablational (PZ) zones created with two commercially available devices in clinical use for radiofrequency (RFA) and microwave ablation (MWA), respectively. Methods: Computer models were used to simulate RFA with a 3-cm Cool-tip applicator and MWA with an Amica-Gen applicator. The Arrhenius model was used to compute the damage index (X). CZ was considered when X > 4.6 (>99% of damaged cells). Regions with 0.6

show abstract

Computed Tomography-Guided Microwave Ablation of Cystic Renal Cell Carcinoma: Assessment of Technique and Complications

Zhou

Herwald

Arellano

2021

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Thermal Field Distributions of Ablative Experiments Using Cyst-mimicking Phantoms

Cited by 7 publications

References 28 publications

Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis

Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis

How large is the periablational zone after radiofrequency and microwave ablation? Computer-based comparative study of two currently used clinical devices

Computed Tomography-Guided Microwave Ablation of Cystic Renal Cell Carcinoma: Assessment of Technique and Complications

Contact Info

Product

Resources

About